Identification of genetic pathways driving Ebola virus disease in humans and targets for therapeutic intervention

  • Daniel A. Achinko, Anton Dormer, Mahesh Narayanan, Elton F. Norman, Muneer Abbas
  • F1000Research, December 2016, Faculty of 1000, Ltd.
  • DOI: 10.12688/f1000research.9778.1

Viral diesease pathways inhibiting Immune response

What is it about?

This publication highlights a common entry route used by several viruses to infect human hosts. Their entry pattern subdues related genetic pathways leading to inhibition of Major Histocompatibility Class I genes.

Why is it important?

This work brings to light the role of LCK a key gene whose role is critical to viral inhibition but viral pathogens turn to control its splicing machinery rendering it non functional. This will guide new therapeutic decisions addressed by our group

Perspectives

Dr Daniel A Achinko
National Institutes of Health

This work is critical and comes at a time when a lot of viral infections and related epidemics like Ebola in West Africa and Rift Valley fever in Kenya and East Africa, are still poorly addressed because of lack of understanding of viral parthenogenesis. This study brings to light a common pathway differentially exploited by viruses for their pathogenic gains. Therefore, identification of pathogenic driver genes and development of cut-across therapy is our focus

open access logoRead Publication

http://dx.doi.org/10.12688/f1000research.9778.1

The following have contributed to this page: Dr Daniel A Achinko, Dr Muneer Abbas, and Dr Anton Dormer